Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Mar 8;32(167):220210.
doi: 10.1183/16000617.0210-2022. Print 2023 Mar 31.

Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis

Greta M Joy  1 , Omri A Arbiv  1 , Carmen K Wong  1 , Stacey D Lok  2 , Nicola A Adderley  3 , Krzysztof M Dobosz  1 , Kerri A Johannson  3 , Christopher J Ryerson  4   5
Affiliations
Meta-Analysis

Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis

Greta M Joy et al. Eur Respir Rev. .

Abstract

Introduction: Interstitial lung disease (ILD) is a frequent manifestation of connective tissue disease (CTD) with substantial variability in prevalence and outcomes reported across CTD subtypes. This systematic review summarises the prevalence, risk factors and ILD patterns on chest computed tomography of CTD-ILD.

Methods: A comprehensive search was performed in Medline and Embase to identify eligible studies. Meta-analyses were completed using a random effects model to determine the pooled prevalence of CTD-ILD and ILD patterns.

Results: 11 582 unique citations were identified with 237 articles included. Pooled prevalence of ILD was 11% in rheumatoid arthritis (95% CI 7-15%), 47% in systemic sclerosis (44-50%), 41% in idiopathic inflammatory myositis (33-50%), 17% in primary Sjögren's syndrome (12-21%), 56% in mixed connective tissue disease (39-72%) and 6% in systemic lupus erythematosus (3-10%). Usual interstitial pneumonia was the most prevalent ILD pattern in rheumatoid arthritis (pooled prevalence of 46%), while nonspecific interstitial pneumonia was the most common ILD pattern in all other CTD subtypes (pooled prevalence range 27-76%). Across all CTDs with available data, positive serology and higher inflammatory markers were risk factors for development of ILD.

Discussion: We identified substantial variability in ILD across CTD subtypes suggesting that CTD-ILD is too heterogenous to be considered a single entity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: G.M. Joy has nothing to disclose. Conflict of interest: O.A. Arbiv has nothing to disclose. Conflict of interest: C.K. Wong has nothing to disclose. Conflict of interest: S.D. Lok has received fees, honoraria, or contracts from University of Saskatchewan CoM, Boehringer Ingelheim, Roche, and AstraZeneca unrelated to this work. Conflict of interest: N.A. Adderley has nothing to disclose. Conflict of interest: K.M. Dobosz has nothing to disclose. Conflict of interest: K.A. Johannson has received fees, honoraria, or contracts from Three Lakes Foundation, Chest Foundation, University of Calgary CSM, University Hospital Foundation, Boehringer Ingelheim, Hoffman-La Roche Ltd, Pliant Therapeutics, Thyron SAB, and PFOX trial all unrelated to this work. Conflict of interest: C.J. Ryerson has received fees, honoraria, or contracts from Boehringer Ingelheim, Hoffman-La Roche Ltd, Pliant Therapeutics, AstraZeneca, Veracyte, Ensho, Cipla Ltd, all unrelated to this work.

Figures

FIGURE 1
FIGURE 1
Identification of studies flow diagram. #: Some studies addressed more than one connective tissue disease (CTD). IIM: idiopathic inflammatory myositis; ILD: interstitial lung disease; MCTD: mixed connective tissue disease; pSS: primary Sjögren's syndrome; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SSc: systemic sclerosis; UCTD: undifferentiated connective tissue disease.
FIGURE 2
FIGURE 2
Pooled prevalence of interstitial lung disease (ILD) in patients with connective tissue disease.
FIGURE 3
FIGURE 3
Metaregression of potential factors influencing heterogeneity of reported prevalence of interstitial lung disease (ILD) within each connective tissue disease. a) Rheumatoid arthritis (RA), b–d) systemic sclerosis (SSc), e–f) idiopathic inflammatory myositis (IIM). There were insufficient data to support meta-regression for primary Sjögren's syndrome, systemic lupus erythematosus, mixed connective tissue disease and undifferentiated connective tissue disease.
FIGURE 4
FIGURE 4
Pooled prevalence of interstitial lung disease patterns by connective tissue disease. Insufficient data were available to support subdivision of non-usual interstitial pneumonia (UIP) patterns in undifferentiated connective tissue disease. LIP: lymphocytic interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; other: other and undifferentiated; OP: organising pneumonia.
See this image and copyright information in PMC

References

    1. Hyldgaard C, Bendstrup E, Pedersen AB, et al. . Interstitial lung disease in connective tissue diseases: survival patterns in a population-based cohort. J Clin Med 2021; 10: 4830. doi:10.3390/jcm10214830 - DOI - PMC - PubMed
    1. Jeganathan N, Sathananthan M. Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 2020; 198: 735–759. doi:10.1007/s00408-020-00383-w - DOI - PubMed
    1. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016; 352: h6819. doi:10.1136/bmj.h6819 - DOI - PMC - PubMed
    1. Travis WD, Costabel U, Hansell DM, et al. . An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748. doi:10.1164/rccm.201308-1483ST - DOI - PMC - PubMed
    1. Wells GA, Shea B, O'Connell D, et al. . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca//programs/clinical_epidemiology/oxford.asp Date last accessed: 17 October 2022.

MeSH terms